Mossman BT, Gee JB: Asbestos-related diseases. N Engl J Med. 1989, 320 (26): 1721-1730. 10.1056/NEJM198906293202604.
Article
CAS
PubMed
Google Scholar
Craighead JE, Mossman BT: The pathogenesis of asbestos-associated diseases. N Engl J Med. 1982, 306 (24): 1446-1455. 10.1056/NEJM198206173062403.
Article
CAS
PubMed
Google Scholar
Browne K: Asbestos-related mesothelioma: epidemiological evidence for asbestos as a promoter. Arch Environ Health. 1983, 38 (5): 261-266. 10.1080/00039896.1983.10544004.
Article
CAS
PubMed
Google Scholar
Vogelzang NJ: Emerging insights into the biology and therapy of malignant mesothelioma. Semin Oncol. 2002, 29 (6 Suppl 18): 35-42.
Article
PubMed
Google Scholar
Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH: A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009, 63 (5): 799-805. 10.1007/s00280-008-0800-0.
Article
CAS
PubMed
Google Scholar
Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN: Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008, 31 (1): 49-54. 10.1097/COC.0b013e3180684181.
Article
CAS
PubMed
Google Scholar
Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL: Diffuse malignant peritoneal mesothelioma–An update on treatment. Cancer Treat Rev. 2012, 38 (6): 605-612. 10.1016/j.ctrv.2011.10.006.
Article
PubMed
Google Scholar
Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, Yoo D: Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol. 2002, 29 (1): 51-61.
Article
PubMed
Google Scholar
Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, Testa JR, Pass HI, Carbone M, Steele C, Mossman BT: Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010, 1203: 7-14. 10.1111/j.1749-6632.2010.05554.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Macura SL, Hillegass JM, Steinbacher JL, MacPherson MB, Shukla A, Beuschel SL, Perkins TN, Butnor KJ, Lathrop MJ, Sayan M, Hekmatyar K, Taatjes DJ, Kauppinen RA, Landry CC, Mossman BT: A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas. J Histochem Cytochem. 2012, 60 (9): 658-674. 10.1369/0022155412452567.
Article
PubMed
PubMed Central
Google Scholar
Gallis KW, Landry CC: Mesoporous silicates and method of making same. 2002, US Patent 6,334,988
Google Scholar
Cheng K, El-Boubbou K, Landry CC: Binding of HIV-1 gp120 glycoprotein to silica nanoparticles modified with CD4 glycoprotein and CD4 peptide fragments. ACS Appl Mater Interfaces. 2012, 4 (1): 235-243. 10.1021/am2013008.
Article
CAS
PubMed
Google Scholar
Cheng K, Blumen SR, MacPherson MB, Steinbacher JL, Mossman BT, Landry CC: Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer. ACS Appl Mater Interfaces. 2010, 2 (9): 2489-2495. 10.1021/am100530t.
Article
CAS
PubMed
PubMed Central
Google Scholar
Blumen SR, Cheng K, Ramos-Nino ME, Taatjes DJ, Weiss DJ, Landry CC, Mossman BT: Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells. Am J Respir Cell Mol Biol. 2007, 36 (3): 333-342. 10.1165/rcmb.2006-0319OC.
Article
CAS
PubMed
Google Scholar
Warheit DB: Inhaled amorphous silica particulates: What do we know about their toxicological profiles?. J Environ Pathol Toxicol Oncol. 2001, 20 (Suppl 1): 133-141.
PubMed
Google Scholar
Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996, 93 (1): 136-140. 10.1073/pnas.93.1.136.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I: Mesothelin expression in human lung cancer. Clin Cancer Res. 2007, 13 (5): 1571-1575. 10.1158/1078-0432.CCR-06-2161.
Article
CAS
PubMed
Google Scholar
Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007, 7: 20-
PubMed
PubMed Central
Google Scholar
Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004, 279 (10): 9190-9198. 10.1074/jbc.M312372200.
Article
CAS
PubMed
Google Scholar
Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I: Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res. 2005, 11 (10): 3814-3820. 10.1158/1078-0432.CCR-04-2304.
Article
CAS
PubMed
Google Scholar
Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008, 44 (1): 46-53. 10.1016/j.ejca.2007.08.028.
Article
CAS
PubMed
Google Scholar
Miettinen M, Sarlomo-Rikala M: Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003, 27 (2): 150-158. 10.1097/00000478-200302000-00002.
Article
PubMed
Google Scholar
Kelly RJ, Sharon E, Pastan I, Hassan R: Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther. 2012, 11 (3): 517-525. 10.1158/1535-7163.MCT-11-0454.
Article
CAS
PubMed
PubMed Central
Google Scholar
Steinbacher JL, Lathrop SA, Cheng K, Hillegass JM, Butnor KJ, Kauppinen RA, Mossman BT, Landry CC: Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection. Small. 2010, 6 (23): 2678-2682. 10.1002/smll.201001447.
Article
CAS
PubMed
PubMed Central
Google Scholar
Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A: Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res. 1987, 47 (12): 3199-3205.
CAS
PubMed
Google Scholar
Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-Nino ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman BT: Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer. 2011, 129 (1): 233-244. 10.1002/ijc.25666.
Article
CAS
PubMed
Google Scholar
Carson FL, Hladik C: Histotechnology: A Self-instructional Text. 1997, Chicago: ASCP Press, 96:
Google Scholar
Sabo-Attwood T, Ramos-Nino ME, Eugenia-Ariza M, Macpherson MB, Butnor KJ, Vacek PC, McGee SP, Clark JC, Steele C, Mossman BT: Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis. Am J Pathol. 2011, 178 (5): 1975-1985. 10.1016/j.ajpath.2011.01.048.
Article
CAS
PubMed
PubMed Central
Google Scholar
Haegens A, van der Vliet A, Butnor KJ, Heintz N, Taatjes D, Hemenway D, Vacek P, Freeman BA, Hazen SL, Brennan ML, Mossman BT: Asbestos-induced lung inflammation and epithelial cell proliferation are altered in myeloperoxidase-null mice. Cancer Res. 2005, 65 (21): 9670-9677. 10.1158/0008-5472.CAN-05-1751.
Article
CAS
PubMed
Google Scholar
de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G, Sparreboom A: Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem. 1999, 266 (2): 216-221. 10.1006/abio.1998.2943.
Article
CAS
PubMed
Google Scholar
Heintz NH, Janssen-Heininger YM, Mossman BT: Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010, 42 (2): 133-139. 10.1165/rcmb.2009-0206TR.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hassan R, Bera T, Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004, 10 (12 Pt 1): 3937-3942.
Article
CAS
PubMed
Google Scholar
Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I: Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009, 15 (16): 5274-5279. 10.1158/1078-0432.CCR-09-0062.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007, 13 (17): 5144-5149. 10.1158/1078-0432.CCR-07-0869.
Article
CAS
PubMed
Google Scholar
Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D: Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010, 16 (24): 6132-6138. 10.1158/1078-0432.CCR-10-2275.
Article
CAS
PubMed
PubMed Central
Google Scholar
Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Eiden JE, Jaffee EM, Laheru DA: A Live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012, 18 (3): 858-868. 10.1158/1078-0432.CCR-11-2121.
Article
CAS
PubMed
Google Scholar
Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olyaee MS, Esfandyari T, Farassati F: Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One. 2012, 7 (4): e33214-10.1371/journal.pone.0033214.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mohamed F, Cecil T, Moran B, Sugarbaker P: A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011, 18 (2): e84-96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yan TD, Black D, Savady R, Sugarbaker PH: A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007, 14 (2): 484-492. 10.1245/s10434-006-9182-x.
Article
PubMed
Google Scholar
Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009, 27 (36): 6237-6242. 10.1200/JCO.2009.23.9640.
Article
PubMed
Google Scholar
Sugarbaker PH, Stuart OA, Eger C: Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract. 2012, 2012: 471205-
PubMed
PubMed Central
Google Scholar
Lewis JS, Lee JA, Underwood JC, Harris AL, Lewis CE: Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol. 1999, 66 (6): 889-900.
CAS
PubMed
Google Scholar
Mantovani A, Schioppa T, Porta C, Allavena P, Sica A: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25 (3): 315-322. 10.1007/s10555-006-9001-7.
Article
PubMed
Google Scholar
Ben-Baruch A: Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006, 16 (1): 38-52. 10.1016/j.semcancer.2005.07.006.
Article
CAS
PubMed
Google Scholar
Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009, 86 (5): 1065-1073. 10.1189/jlb.0609385.
Article
CAS
PubMed
Google Scholar
Harris AL: Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2 (1): 38-47. 10.1038/nrc704.
Article
CAS
PubMed
Google Scholar
Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA: Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer. 2006, 51 (1): 53-59. 10.1016/j.lungcan.2005.07.010.
Article
CAS
PubMed
Google Scholar
Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF: The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005, 11 (24 Pt 1): 8782-8788.
Article
CAS
PubMed
Google Scholar
Jang SH, Wientjes MG, Lu D, Au JL: Drug delivery and transport to solid tumors. Pharm Res. 2003, 20 (9): 1337-1350. 10.1023/A:1025785505977.
Article
CAS
PubMed
Google Scholar